Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes

Diabetes Technology and Therapeutics

Volumn 21, Issue 9, 2019, Pages 471-477

  Danne, Thomas ^a   Pettus, Jeremy ^b   Giaccari, Andrea ^c   Cariou, Bertrand ^d   Rodbard, Helena ^e   Weinzimer, Stuart A ^f   Bonnemaire, Mireille ^g   Sawhney, Sangeeta ^h   Stewart, John ^g   Wang, Stella ^g   Castro, Rita De Cassia ^g   Garg, Satish K ⁱ  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d L INSTITUT DU THORAX   (France)

^e Endocrine and Metabolic Consultants   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SANOFI   (France)

^h LEXICON PHARMACEUTICALS INC   (United States)

ⁱ UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Efficacy beyond HbA1c; HbA1c; Hypoglycemia; inTandem; SGLT1 SGLT2 inhibitors; Sotagliflozin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLYCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NOCTURNAL HYPOGLYCEMIA; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADMINISTRATION AND DOSAGE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCATED HEMOGLOBIN A; GLYCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85071159069     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2019.0157     Document Type: Article

References (34)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.
3. Brod M, Wolden M, Groleau D, Bushnell DM: Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2. J Med Econ 2014;17:11-20.
4. Brod M, Wolden M, Christensen T, Bushnell DM: Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health 2013; 16:1140-1149.
5. Brod M, Christensen T, Thomsen TL, Bushnell DM: The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14: 665-671.
6. Foos V, Varol N, Curtis BH, et al.: Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ 2015; 18:420-432.
7. Aronson R, Galstyan G, Goldfracht M, et al.: Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetes Res Clin Pract 2018;138:35-43.
8. Seaquist ER, Anderson J, Childs B, et al.: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-1395.
9. Ratner RE, Dickey R, Fineman M, et al.: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004;21:1204-1212.
10. Bode BW, Garg SK: The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract 2016;22:220-230.
11. Garg SK, Henry RR, Banks P, et al.: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337-2348.
12. Buse JB, Garg SK, Rosenstock J, et al.: Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study. Diabetes Care 2018;41:1970-1980.
13. Danne T, Cariou B, Banks P, et al.: HbA1c and hypoglycemia reduction at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care 2018;41: 1981-1990.
14. Musso G, Gambino R, Cassader M, Paschetta E: Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:l1328.
15. Henry RR, Thakkar P, Tong C, et al.: Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38:2258-2265.
16. Dandona P, Mathieu C, Phillip M, et al.: Efficacy and safety of Dapagliflozin In Patients With Inadequately Controlled Type 1 Diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5:864-876.
17. Mathieu C, Dandona P, Gillard P, et al.: Efficacy and safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care 2018;41: 1938-1946.
18. Rosenstock J, Marquard J, Laffel LM, et al.: Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 2018;41:2560-2569.
19. Lapuerta P, Zambrowicz B, Strumph P, Sands A: Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res 2015;12:101-110.
20. Dobbins RL, Greenway FL, Chen L, et al.: Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 2015;308:G946-G954.
21. Zambrowicz B, Ogbaa I, Frazier K, et al.: Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagonlike peptide 1, and peptide tyrosine tyrosine in a dosetiming study in healthy subjects. Clin Ther 2013;35:1162-1173.e1168.
22. International Hypoglycaemia Study Group: Glucose concentrations of less than 3.0 mmol/L (54mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017;40:155-157.
23. American Diabetes Association: 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care 2019;42(Suppl 1):S61-S70.
24. Martyn-Nemeth P, Quinn L, Penckofer S, et al.: Fear of hypoglycemia: influence on glycemic variability and selfmanagement behavior in young adults with type 1 diabetes. J Diabetes Complications 2017;31:735-741.
25. Anderbro T, Gonder-Frederick L, Bolinder J, et al.: Fear of hypoglycemia: relationship to hypoglycemic risk and psychological factors. Acta Diabetol 2015;52:581-589.
26. Rankin D, Elliott J, Heller S, et al.: Experiences of hypoglycaemia unawareness amongst people with type 1 diabetes: a qualitative investigation. Chronic Illn 2014;10: 180-191.
27. Danne T, Cariou B, Buse JB, et al.: Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program. Diabetes Care 2019;42:919-930.
28. Foster NC, Beck RW, Miller KM, et al.: State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther 2019;21: 66-72.
29. Centers for Disease Control and Prevention: National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, 2017.
30. Danne T, Garg S, Peters AL, et al.: International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019;42: 1147-1154.
31. Garg SK, Strumph P: Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med 2018;378: 967-968.
32. European Medicines Agency: CHMP summary of positive opinion for Zynquista. February 28, 2019. https://www.ema .europa.eu/en/medicines/human/summaries-opinion/zynquista (accessed May 15, 2019).
33. European Medicines Agency: First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. February 1, 2019. https://www.ema.europa.eu/en/news/first-oral-add-treatment-insulin-treatment-certain-patientstype-1-diabetes (accessed April 8, 2019).
34. Garg SK, Peters AL, Buse JB, Danne T: Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol Ther 2018;20:571-575.